Law and Regulations

Focused on lowering costs and saving patients money, the plan is focused on drug prices, insurance premiums, and some of health care’s largest companies.

This December 2025 order is an extension of HHS’ recommendation to reconsider marijuana as a Schedule III medication in 2023.

During his second term, President Trump has bolstered his approach at lowering prescription drug prices in the US through innovative yet unprecedented decisions.

Ron Lanton III, Esq, provides nuance to the current state of pharmacy sustainability and how the MFN drug pricing policy could impact the industry.

A conversation with NCPDP’s Rick Sage explored the lasting effects on pharmacy stemming from the record-breaking government shutdown.

Researchers explore highly engaged social media posts related to glucagon-like peptide-1 receptor agonists, attention deficit/hyperactivity disorder stimulants, and autoimmune biologics.

This episode explores ongoing developments in pharmacy law, specifically for independent pharmacies and their representatives who attended the 2025 NCPA Convention & Expo.

The final part of our interview with Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, focuses on the relationships between state- and federal-level PBM reform.

At the NCPA 2025 Annual Convention & Expo, Lucas Morgan, Esq, shareholder with Buchanan Ingersoll & Rooney, joined us to discuss ongoing PBM legislation in the state of Arkansas.

In part 2 of a roundtable on the Most Favored Nation Executive Order for prescription drugs, experts gathered to discuss recent developments and how they’ll impact the policy’s future.

As shortages end, pharmacies that compound GLP-1s face lawsuits, stricter board oversight, and tougher FDA enforcement.

The panel discussion features pharmacy leaders, policy experts, and well-known legal minds discussing the Most Favored Nation drug policy and its overarching implications.

In part 3 of our interview with Joey Mattingly, PharmD, MBA, PhD, he discusses potential government policies for reducing pharmacy closures.

Researchers gathered a group of adolescent-serving clinicians and asked them about their confidence in helping patients with abortion access.

Senators Warner and Thune reintroduced the ECAPS legislation improving both seniors’ access to care and pharmacists’ ability to get reimbursed for clinical services.

Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.

Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.

At AAP 2025, Ron Friedman discussed best practices for responding to a DEA inspection, how to identify any red flags, and best practices for dispensing.

A conversation with Rob Frankil, RPh, executive director of the Philadelphia Association of Retail Druggists.

Explore key legislative actions changing pharmacy practice in 2025 and beyond.

Senators Elizabeth Warren and Tina Smith have reintroduced the Pharmaceutical Supply Chain Defense and Enhancement Act originally established in 2020.

Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.

The Affordable Care Act was passed in 2010 to make health care and prescription medicine more accessible. Did it succeed?